Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection

Luis D. Giavedoni, Vicente Flanelles, Nancy Haigwood, Shabbir Ahmad, John D. Kluge, Marta L. Marthas, Murray B. Gardner, Paul A. Luciw, Tilahun D. Yilma

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Simian immunodeficiency virus (SIV) infection of rhesus macaques is a model for human immunodeficiency virus (HIV) infection in humans. Inactivated and modified live whole-virus vaccines have provided limited protective immunity against SIV in rhesus macaques. Because of safety concerns in the use of inactivated and live whole-virus vaccines, we evaluated the protective immunity of vaccinia virus recombinants expressing the surface glycoprotein (gp!30) of SIVmac and subunit preparations of gp130 expressed in mammalian cells (CHO). Three groups of animals were immunized with recombinant SIV gp130. The first group received SIV gp130 purified from genetically engineered CHO cells (cSIVgp130), the second group was vaccinated with recombinant vaccinia virus expressing SIVmac gp130 (vSIVgp130), and the third group was first primed with vSrVgp130 and then given a booster immunization with cSIVgp130. Although anti-gp130 binding antibodies were elicited in all three groups, neutralizing antibodies were transient or undetectable. None of the immunized animals resisted intravenous challenge with a low dose of cell-free virus. However, the group primed with vSrVgp130 and then boosted with cSIVgp130 had the lowest antigen load (p27) compared with the other groups. The results of these studies suggest that immunization of humans with HIV type 1 surface glycoprotein may not provide protective immunity against virus infection.

Original languageEnglish (US)
Pages (from-to)577-583
Number of pages7
JournalJournal of Virology
Volume67
Issue number1
StatePublished - Jan 1993
Externally publishedYes

Fingerprint

Simian immunodeficiency virus
Virus Diseases
Macaca mulatta
Immunity
Simian Immunodeficiency Virus
CHO Cells
Vaccinia virus
Membrane Glycoproteins
immune response
Viruses
viruses
immunity
Vaccines
Infection
infection
Secondary Immunization
glycoproteins
vaccines
Neutralizing Antibodies
HIV-1

ASJC Scopus subject areas

  • Immunology

Cite this

Giavedoni, L. D., Flanelles, V., Haigwood, N., Ahmad, S., Kluge, J. D., Marthas, M. L., ... Yilma, T. D. (1993). Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. Journal of Virology, 67(1), 577-583.

Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. / Giavedoni, Luis D.; Flanelles, Vicente; Haigwood, Nancy; Ahmad, Shabbir; Kluge, John D.; Marthas, Marta L.; Gardner, Murray B.; Luciw, Paul A.; Yilma, Tilahun D.

In: Journal of Virology, Vol. 67, No. 1, 01.1993, p. 577-583.

Research output: Contribution to journalArticle

Giavedoni, LD, Flanelles, V, Haigwood, N, Ahmad, S, Kluge, JD, Marthas, ML, Gardner, MB, Luciw, PA & Yilma, TD 1993, 'Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection', Journal of Virology, vol. 67, no. 1, pp. 577-583.
Giavedoni, Luis D. ; Flanelles, Vicente ; Haigwood, Nancy ; Ahmad, Shabbir ; Kluge, John D. ; Marthas, Marta L. ; Gardner, Murray B. ; Luciw, Paul A. ; Yilma, Tilahun D. / Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. In: Journal of Virology. 1993 ; Vol. 67, No. 1. pp. 577-583.
@article{8ca86e20fe434f1182e1a8ba82e56f67,
title = "Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection",
abstract = "Simian immunodeficiency virus (SIV) infection of rhesus macaques is a model for human immunodeficiency virus (HIV) infection in humans. Inactivated and modified live whole-virus vaccines have provided limited protective immunity against SIV in rhesus macaques. Because of safety concerns in the use of inactivated and live whole-virus vaccines, we evaluated the protective immunity of vaccinia virus recombinants expressing the surface glycoprotein (gp!30) of SIVmac and subunit preparations of gp130 expressed in mammalian cells (CHO). Three groups of animals were immunized with recombinant SIV gp130. The first group received SIV gp130 purified from genetically engineered CHO cells (cSIVgp130), the second group was vaccinated with recombinant vaccinia virus expressing SIVmac gp130 (vSIVgp130), and the third group was first primed with vSrVgp130 and then given a booster immunization with cSIVgp130. Although anti-gp130 binding antibodies were elicited in all three groups, neutralizing antibodies were transient or undetectable. None of the immunized animals resisted intravenous challenge with a low dose of cell-free virus. However, the group primed with vSrVgp130 and then boosted with cSIVgp130 had the lowest antigen load (p27) compared with the other groups. The results of these studies suggest that immunization of humans with HIV type 1 surface glycoprotein may not provide protective immunity against virus infection.",
author = "Giavedoni, {Luis D.} and Vicente Flanelles and Nancy Haigwood and Shabbir Ahmad and Kluge, {John D.} and Marthas, {Marta L.} and Gardner, {Murray B.} and Luciw, {Paul A.} and Yilma, {Tilahun D.}",
year = "1993",
month = "1",
language = "English (US)",
volume = "67",
pages = "577--583",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection

AU - Giavedoni, Luis D.

AU - Flanelles, Vicente

AU - Haigwood, Nancy

AU - Ahmad, Shabbir

AU - Kluge, John D.

AU - Marthas, Marta L.

AU - Gardner, Murray B.

AU - Luciw, Paul A.

AU - Yilma, Tilahun D.

PY - 1993/1

Y1 - 1993/1

N2 - Simian immunodeficiency virus (SIV) infection of rhesus macaques is a model for human immunodeficiency virus (HIV) infection in humans. Inactivated and modified live whole-virus vaccines have provided limited protective immunity against SIV in rhesus macaques. Because of safety concerns in the use of inactivated and live whole-virus vaccines, we evaluated the protective immunity of vaccinia virus recombinants expressing the surface glycoprotein (gp!30) of SIVmac and subunit preparations of gp130 expressed in mammalian cells (CHO). Three groups of animals were immunized with recombinant SIV gp130. The first group received SIV gp130 purified from genetically engineered CHO cells (cSIVgp130), the second group was vaccinated with recombinant vaccinia virus expressing SIVmac gp130 (vSIVgp130), and the third group was first primed with vSrVgp130 and then given a booster immunization with cSIVgp130. Although anti-gp130 binding antibodies were elicited in all three groups, neutralizing antibodies were transient or undetectable. None of the immunized animals resisted intravenous challenge with a low dose of cell-free virus. However, the group primed with vSrVgp130 and then boosted with cSIVgp130 had the lowest antigen load (p27) compared with the other groups. The results of these studies suggest that immunization of humans with HIV type 1 surface glycoprotein may not provide protective immunity against virus infection.

AB - Simian immunodeficiency virus (SIV) infection of rhesus macaques is a model for human immunodeficiency virus (HIV) infection in humans. Inactivated and modified live whole-virus vaccines have provided limited protective immunity against SIV in rhesus macaques. Because of safety concerns in the use of inactivated and live whole-virus vaccines, we evaluated the protective immunity of vaccinia virus recombinants expressing the surface glycoprotein (gp!30) of SIVmac and subunit preparations of gp130 expressed in mammalian cells (CHO). Three groups of animals were immunized with recombinant SIV gp130. The first group received SIV gp130 purified from genetically engineered CHO cells (cSIVgp130), the second group was vaccinated with recombinant vaccinia virus expressing SIVmac gp130 (vSIVgp130), and the third group was first primed with vSrVgp130 and then given a booster immunization with cSIVgp130. Although anti-gp130 binding antibodies were elicited in all three groups, neutralizing antibodies were transient or undetectable. None of the immunized animals resisted intravenous challenge with a low dose of cell-free virus. However, the group primed with vSrVgp130 and then boosted with cSIVgp130 had the lowest antigen load (p27) compared with the other groups. The results of these studies suggest that immunization of humans with HIV type 1 surface glycoprotein may not provide protective immunity against virus infection.

UR - http://www.scopus.com/inward/record.url?scp=0027392781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027392781&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 577

EP - 583

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 1

ER -